德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

已收盘 07-21 16:08:06

4.100

-0.040

-0.97%

最高4.250	最低3.950	成交量160.07万
今开4.200	昨收4.140	日振幅7.25%
总市值27.80亿	流通市值27.80亿	总股本6.78亿
成交额652.66万	换手率0.24%	流通股本6.78亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":4.1,"timestamp":1784621286007,"preClose":4.14,"halted":0,"volume":1600730,"delay":0,"changeRate":-0.00966183574879228,"floatShares":678000000,"shares":678000000,"eps":-0.44035742852213733,"marketStatus":"已收盘","change":-0.04,"latestTime":"07-21 16:08:06","open":4.2,"high":4.25,"low":3.95,"amount":6526633,"amplitude":0.072464,"askPrice":4.1,"askSize":3000,"bidPrice":4.09,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.45194578190429885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784683800000},"marketStatusCode":5,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":4.14,"openAndCloseTimeList":[[1784597400000,1784606400000],[1784610000000,1784620800000]],"volumeRatio":0.845058,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"1185829185","title":"德琪医药-B：7月20日回购24.3万股股份，耗资约100.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185829185","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185829185?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:02","pubTimestamp":1784541768,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月20日发布公告，披露当日在香港联交所回购普通股243,000股，占该次回购前公司已发行股份总数的0.0358%。回购价格介乎每股港币4.07元至4.20元，累计支付总金额合计约港币100.30万。回购完成后，公司已发行股本为677,662,132股，库存股份增加至1,784,500股，总股本仍维持在679,446,632股。公告显示，此次回购基于2026年6月10日通过的购回授权，该授权可供回购的股份总数为67,924,413股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B：7月20日回购24.3万股股份，耗资约100.30万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652423294","title":"德琪医药-B(06996)7月20日斥资100.3万港元回购24.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652423294","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652423294?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:01","pubTimestamp":1784541677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，该公司于2026年7月20日斥资100.3万港元回购24.3万股股份，每股回购价格为4.07-4.2港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06996","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176825644","title":"德琪医药-B回购499,000股股份，耗资约200.34万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176825644","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176825644?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:00","pubTimestamp":1784282455,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月17日发布公告，披露该公司于香港联交所场内回购499,000股普通股，占本次回购前公司已发行股份总数约0.0736%。回购价格介乎每股3.86港元至4.15港元之间，合计使用资金约200.34万港元。公告显示，本次回购完成后，公司已发行股份数量为677,905,132股，库藏股数为1,541,500股，合计股份总数为679,446,632股。公司亦披露，于2026年6月10日获得的股份回购授权可再回购最高达67,924,413股，此前已合计回购1,339,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购499,000股股份，耗资约200.34万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102919041","title":"德琪医药-B回购22.55万股股份，总额约100.39万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102919041","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102919041?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:11","pubTimestamp":1784196697,"startTime":"0","endTime":"0","summary":"2026年7月16日，德琪医药-B在香港联交所披露翌日披露报表，公司于当日通过场内交易回购普通股225,500股，占回购前公司已发行股本约0.0332%。回购价格在每股4.37港元至4.54港元之间，涉资合计约100.39万港元。公司购回授权于2026年6月10日通过，授权范围内尚可回购67,924,413股。此外，公司确认本次回购活动符合香港联合交易所有限公司证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购22.55万股股份，总额约100.39万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651686443","title":"德琪医药-B(06996)7月16日耗资约100.39万港元回购22.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651686443","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651686443?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:08","pubTimestamp":1784196532,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)公布，2026年7月16日耗资约100.39万港元回购22.55万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","06996","159992","BK1161","06978","06622","09688","09606","09995","02137","02268","IBBQ","MEDX","02269","03347","03759","06606","01672","02359","06618","01801","00241","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1135497441","title":"德琪医药-B于7月15日回购1.4万股股份，总额约6.17万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135497441","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135497441?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:12","pubTimestamp":1784110340,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月15日发布翌日披露报表，披露公司在香港联交所进行股份回购的最新情况。公告显示，2026年7月15日，德琪医药-B于港交所回购14,000股普通股，占该次回购前公司已发行股本约0.0021%。每股回购价格为港币4.41元，总计斥资约6.17万港元。根据公告，德琪医药-B此前于2026年6月10日通过购回授权，授权公司可回购的股份总数为67,924,413股。公司在公告中确认，已遵守香港联交所证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B于7月15日回购1.4万股股份，总额约6.17万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107041912","title":"德琪医药-B回购2.30万股股份，耗资约9.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107041912","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107041912?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:16","pubTimestamp":1784027779,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月14日发布公告，披露其于香港联交所场内回购公司普通股。此次回购数量为2.30万股，约占本次回购前已发行股本的0.0034%。回购价格每股在港币4.30元至4.33元之间，总支出约9.94万港元。回购完成后，公司最新已发行股本为678,643,632股，库藏股数量增至803,000股。公司同时披露，根据上市规则要求，自本次回购后，至2026年8月13日为止，公司暂不进行新股发行或再次出售、转让已持有的库藏股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购2.30万股股份，耗资约9.94万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170377","title":"德琪医药-B(06996)7月14日斥资9.9万港元回购2.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651170377?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:15","pubTimestamp":1784027722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，于2026年7月14日斥资9.9万港元回购2.3万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110954406","title":"德琪医药-B：7月13日回购9.15万股，耗资约39.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110954406","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110954406?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:01","pubTimestamp":1783944104,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月13日发布公告，披露当日于香港联交所场内回购普通股9.15万股，约占公告前已发行股本的0.0135%。回购价介乎每股4.23港元至4.31港元，总金额约39.21万港元。本次回购完成后，公司已发行股本变动为678,666,632股，库存股份数量增至780,000股，总已发行股本保持在679,446,632股。公司表示，本次回购基于2026年6月10日通过的购回授权，授权可回购股份总数为67,924,413股。截至目前，公司已回购577,500股，占授权当日已发行股份总数的0.085%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"德琪医药-B：7月13日回购9.15万股，耗资约39.21万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161182179","title":"德琪医药-B收取优时比6000万美元ATG-201首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1161182179","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161182179?lang=zh_cn&edition=full","pubTime":"2026-07-13 12:05","pubTimestamp":1783915532,"startTime":"0","endTime":"0","summary":"2026年7月13日，德琪医药-B（06996）发布自愿公告称，已从优时比（UCB）收到6,000万美元的ATG-201全球独家授权协议首付款。\n\\n\\n根据公告，德琪医药-B曾于2026年3月4日公告，与优时比就CD19/CD3双特异性T细胞銜接器（TCE）抗体ATG-201签署全球独家授权协议。\n\\n\\n公司表示，本次首付款的到账将进一步巩固集团现金状况，为推进创新药物管线开发及惠及更多患者提供财务支持。\n\\n\\n德琪医药-B同时提示，ATG-201最终可能无法成功开发及商业化，提醒投资者在买卖公司证券时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651216001","title":"德琪医药：自优时比(UCB)收到6000万美元ATG-201首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2651216001","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651216001?lang=zh_cn&edition=full","pubTime":"2026-07-13 12:03","pubTimestamp":1783915427,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","BK1191","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137027661","title":"德琪医药-B：7月10日回购23.85万股，耗资约100.32万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137027661","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137027661?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:52","pubTimestamp":1783684371,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月10日公告，已于香港联交所场内回购238,500股普通股，约占本次行动前公司已发行股本约0.0351%。本次回购每股价格介乎港币3.96元至4.32元，总计耗资约100.32万港元。该次回购依据2026年6月10日通过的股份购回授权进行，授权下可回购的股份总数仍剩余67,924,413股。截至目前，公司已合计回购486,000股，占授权通过当日已发行股本数目的约0.0716%。公司同时确认，此次回购行为已遵守香港联合交易所有限公司证券上市规则及相关适用法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B：7月10日回购23.85万股，耗资约100.32万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907248","title":"港股异动 | 德琪医药-B(06996.HK)涨超7% 近期与K2达成ATG-106独家授权协议 公司TCE平台进入BD持续兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907248?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:56","pubTimestamp":1783666614,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","06996","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650136921","title":"德琪医药-B(06996.HK)7月9日斥资99.89万港元回购24.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650136921","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650136921?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:15","pubTimestamp":1783599358,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06996","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120407072","title":"德琪医药-B：7月9日回购24.75万股，涉资约99.89万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120407072","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120407072?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:15","pubTimestamp":1783599341,"startTime":"0","endTime":"0","summary":"德琪医药有限公司（股票代码：06996）于2026年7月9日发布公告，披露当日通过香港联交所场内回购24.75万股普通股，占当日前已发行股本约0.0364%。本次回购每股价格介乎港币3.96元至4.07元，总金额约99.89万港元。回购完成后，公司已发行股本总数为678,996,632股，库藏股增加至450,000股。\n公告显示，公司购回授权于2026年6月10日获得通过，授权最大可回购股数为67,924,413股，本次已回购24.75万股。公司确认本次股份购回已遵守香港联交所证券上市规则及相关法律法规的规定。\n本公告由公司主席梅建明博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B：7月9日回购24.75万股，涉资约99.89万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199382104","title":"德琪医药-B6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1199382104","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199382104?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:26","pubTimestamp":1783329990,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月6日发布2026年6月股份变动月报表，报告期为2026年6月1日至2026年6月30日。根据公告，该公司已发行股份及注册股本的数量在上述期间内均保持不变。公告显示，截至6月30日，德琪医药-B的注册股本依旧保持在2,000,000,000股普通股，面值每股0.0001美元，总额200,000美元。行使的124,000份期权通过受托人持有的现有股份转让方式予以满足，因此本月无新增发行股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646844901","title":"德琪医药-B(06996)拟进行市场内股份购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2646844901","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646844901?lang=zh_cn&edition=full","pubTime":"2026-06-25 06:59","pubTimestamp":1782341960,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，其拟根据公司股东于2026年6月10日举行的股东周年大会上授予董事会的一般授权，行使其相关权力，以购回至多6792.44万股公司股份，即于股东周年大会日期已发行股份总数的10%。于2026年6月24日，董事会已决议动用股份购回授权，并根据市况不时于公开市场按最高总代价5000万港元购回股份。董事会认为建议股份购回符合公司及其股东整体最佳利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646284490","title":"德琪医药-B(06996.HK)拟进行市场内股份购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2646284490","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646284490?lang=zh_cn&edition=full","pubTime":"2026-06-25 06:59","pubTimestamp":1782341960,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06996","BK1574","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073562","title":"德琪医药拟以TCE产品为创新资产“注入”新公司 实现“出海”","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073562","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073562?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:44","pubTimestamp":1782135840,"startTime":"0","endTime":"0","summary":"德琪医药通过将自身的创新资产导入K2，依托K2的跨技术平台与跨地域的药物发现与开发能力，实现“出海”。该模式也被称为中国创新药的“NewCo”“出海”模式。德琪医药是一家成立于2017年的创新药研发公司，该公司的创始人梅建明博士拥有近20年跨国药企肿瘤研发经验。同时，德琪医药始终坚定自主研发。梅建明表示，本次NewCo合作，是德琪全球化战略的关键落地，也为国内Biotech提供全新“出海”范本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-06-22/doc-inieiatn2356680.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-06-22/doc-inieiatn2356680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1191","06996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":-0.0612},{"period":"1month","weight":0.2176},{"period":"3month","weight":-0.2983},{"period":"6month","weight":0.1564},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0923}],"compareEarnings":[{"period":"1week","weight":0.0384},{"period":"1month","weight":0.0509},{"period":"3month","weight":-0.0508},{"period":"6month","weight":-0.0542},{"period":"1year","weight":0.0128},{"period":"ytd","weight":-0.019}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034689},{"month":5,"riseRate":0.5,"avgChangeRate":0.014763},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.127204},{"month":7,"riseRate":0.333333,"avgChangeRate":0.028048},{"month":8,"riseRate":0.4,"avgChangeRate":-0.030428},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020432},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}